Raydiant Oximetry Launches IDE Pilot Study at LSU Health Shreveport to Advance Fetal Monitoring Technology
SAN RAMON, CA, November 5, 2025 — Raydiant Oximetry, Inc., a clinical-stage medical device company pioneering innovations in fetal monitoring through advanced biophotonics and machine learning, today announced the initiation of an Investigational Device Exemption (IDE) Pilot Study at Louisiana State University Health Shreveport (LSUHS).
Raydiant Oximetry Successfully Completes 35-Patient Early Feasibility Study at Eastern Virginia Medical School at Old Dominion University
SAN RAMON, Calif., October 16, 2025 — Raydiant Oximetry, Inc., a clinical-stage medical device company pioneering fetal monitoring innovations through advanced biophotonics and machine learning, today announced the successful completion of a 35-patient Early Feasibility Study (EFS) at Macon & Joan Brock Virginia Health Sciences Eastern Virginia Medical School (EVMS) at Old Dominion University.
Raydiant Oximetry Names Michael Nagel to Lead the Company into its Device Commercialization Stage as CEO
SAN RAMON, CA, UNITED STATES, September 16, 2025 — Raydiant Oximetry, Inc. a clinical-stage medical device company developing fetal monitoring innovations using advanced biophotonics and machine learning to improve outcomes during childbirth, today announced the appointment of Michael Nagel as Chief Executive Officer.
GE HealthCare and Raydiant Oximetry accelerate innovation in fetal oxygen saturation technology
GE HealthCare and Raydiant Oximetry, Inc. today announced a joint development initiative to enhance fetal monitoring capabilities that could strengthen the support of clinical decision-making during labor. This effort leverages the combined expertise and technology of the two companies to advance fetal oxygen saturation monitoring technology with the goal of enhancing the detection of fetal […]
Raydiant Oximetry Secures $1 Million Grant to Advance Fetal Monitoring Technology
Raydiant Oximetry, Inc., a clinical-stage medical device company developing innovations to keep mothers and babies safe during childbirth, has announced the receipt of a $1 million grant from the Bill & Melinda Gates Foundation.
Raydiant Oximetry Kicks Off Series B Financing Round with an Investment from March of Dimes
Raydiant Oximetry, Inc., announced that it has received an investment from the March of Dimes Innovation Fund to kick off its Series B financing round.
AngelMD Portfolio Company Raydiant Oximetry Awarded FDA Breakthrough Device Status
The accelerated path to approval through the breakthrough device program will enable better care to millions of mothers and babies during childbirth.
Fogarty Innovation Graduate Raydiant Oximetry Raises $5 Million in Oversubscribed Series A2 Financing Round to Support Clinical Study
The funding was led by Avestria Ventures, which invests in early-stage women’s health companies, and syndicated by KOFA Healthcare, V-Capital, Band of Angels, FemHealth Ventures, RHIA Ventures, SteelSky Ventures and Tri-Valley Ventures.
Raydiant Oximetry Receives $3 Million Grant to Advance Its Innovative Technology
Raydiant Oximetry, a Fogarty Innovation graduate, is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth and recently received a grant from the government of Ireland for approximately $3 million.
Raydiant Oximetry Raises Series A Funding; Graduates from Fogarty Institute.
Raydiant Oximetry, a Fogarty Institute company that is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth, has closed a $5.6 million Series A funding round led by VCapital.